Kevin Paul Raisch

Title: Kevin Paul Raisch: Innovator in Anti-Epidermal Growth Factor Receptor Antibodies

Introduction

Kevin Paul Raisch is a notable inventor based in Birmingham, AL (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibodies targeting the epidermal growth factor receptor (EGFR). With a total of two patents to his name, Raisch's work has the potential to impact therapeutic and diagnostic applications.

Latest Patents

Raisch's latest patents focus on human anti-epidermal growth factor receptor single-chain antibodies. These antibodies were isolated from a human IgM phage display library using purified epidermal growth factor receptor as the antigen. Two isolates with different amino acid sequences were identified by ELISA as specific to the epidermal growth factor receptor. The single-chain variable fragments (scFvs) bind to both the full-length epidermal growth factor receptor and its truncated or mutated forms on human cells. These anti-EGFR-scFvs are poised to be useful as therapeutic and diagnostic agents.

Career Highlights

Kevin Paul Raisch is associated with the UAB Research Foundation, where he continues to advance his research in the field of biotechnology. His innovative work has garnered attention and recognition within the scientific community.

Collaborations

Raisch has collaborated with esteemed colleagues such as David T. Curiel and James Alan Bonner. These partnerships have contributed to the advancement of his research and the development of his patented technologies.

Conclusion

Kevin Paul Raisch is a prominent inventor whose work on anti-epidermal growth factor receptor antibodies holds promise for future therapeutic and diagnostic applications. His contributions to biotechnology are noteworthy and reflect his commitment to innovation in the field.